Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities

<p style="margin-bottom: 1rem; color: rgb(40, 57, 137); font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-size: 17.56px; background-color: rgb(255, 255, 255);">This paper focuses on expanding access to biotherapeutics in low- and middle-income countries (LMICs) through public health non-exclusive voluntary intellectual property licensing.</p><p style="margin-bottom: 1rem; color: rgb(40, 57, 137); font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-size: 17.56px; background-color: rgb(255, 255, 255);"><span style="font-weight: var(--font-regular);">The key elements identified as relevant to support access to affordable biosimilars in LMICs through licensing include:</span></p><p style="margin-bottom: 1rem; color: rgb(40, 57, 137); font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-size: 17.56px; background-color: rgb(255, 255, 255);"><ul><li><span style="font-weight: var(--font-regular);">Prioritising potential biotherapeutic targets according to their potential for public health impact</span></li><li><span style="font-weight: var(--font-regular);">Supporting biosimilar product and clinical development</span></li><li><span style="font-weight: var(--font-regular);">Facilitating biosimilars’ entry and use in LMICs</span></li></ul></p>